Recent news on Follistim

Hospital studies new in-vitro fertilization procedure  -  May 22, 2007
cw2.com,Conducted by Reproductive Endocrinologist Dr. Deborah Minjarez, the clinical trial is for an FDA approved drug known as Follistim.

When nature and science fail, women adapt  -  May 13, 2007
Miami Herald,Although she knew that Follistim, an ovulation-inducing drug, would make her fibroids grow, she willingly injected herself. She tried in vitro fertilization

Follistim(R) introduced in Japan in a further indication for the ...  -  Apr 11, 2007
PipelineReview.com (press release),Follistim(R), the first recombinant FSH approved in Japan for use in IVF and ICSI, is now also available in Japan for the induction of ovulation in

Follistim Introduced in Japan in a Further Indication for the ...  -  Apr 11, 2007
PharmaLive.com (press release),Follistim's availability in this new indication means that women and their doctors in Japan now have at their disposal a modern fertility treatment in a

Akzo Nobel's fertility hormone also available in Japan for ...  -  Apr 11, 2007
ABCmoney.co.uk,AMSTERDAM (Thomson Financial) - Akzo Nobel NV said via its unit Organon BioSciences that its infertility drug Follistim is now also available in Japan for

Amsterdam shares slightly higher midday; oil prices keep Shell in ...  -  Apr 11, 2007
Forbes,Akzo Nobel gave up 0.07 pct at 57.00 while the company announced that its infertility drug Follistim is now also available in Japan via its Organon unit.

Amsterdam shares close lower on negative Wall St; Rodamco falls UPDATE  -  Apr 11, 2007
Forbes,Earlier, the company's Organon BioSciences division said that its infertility drug Follistim is now also available in Japan for the induction of ovulation

Schering-Plough buys Organon for $14.4b  -  Mar 28, 2007
IndUS Business Journal,Organon had reported sales of $3.4 billion in 2006, including leading products such as Follistim/Puregon, a follicle-stimulating hormone for infertility;

Schering-Plough CEO: Organon purchase right time for company  -  Mar 20, 2007
MarketWatch...business Organon, which sells an infertility treatment under the brands Follistim and Puregon, and a muscle relaxant sold as Esmeron and Zemuron.

Schering-Plough's Organon buy looks good business for all  -  Mar 13, 2007
Pharma Times (subscription),...receive a significant revenue boost from Organon's contraceptives (notably NuvaRing) and infertility treatment Puregon/Follistim (follitropin beta).

Schering-Plough buys Organon for $14.4 billion  -  Mar 12, 2007
Pharmaceutical Business ReviewOrganon, had sales of $3.4 billion in 2006, including leading products such as Follistim/Puregon, a follicle-stimulating hormone for infertility;

Schering-Plough to Acquire Organon BioSciences for $14.4 Billion  -  Mar 12, 2007
NJBIZ,The pharmaceutical business, Organon, had sales of $3.4 billion in 2006, including products such as Follistim/Puregon, a follicle-stimulating hormone for

Schering-Plough buys Organon for $14B  -  Mar 12, 2007
United Press International...including $3.4 billion in pharmaceuticals, which was comprised predominantly of sales from Follistim, Puregon, Esmeron/Zemuron and NuvaRing.

Schering-Plough buys Organon for 11 billion euros  -  Mar 12, 2007
Pharma Times (subscription),8% to 2.61 billion euros in 2006, driven by its firm's contraceptives (notably NuvaRing) and infertility treatment Puregon/Follistim (follitropin beta).

Schering-Plough to acquire Organon BioSciences  -  Mar 14, 2007
Drovers (subscription),2007), including leading products such as Follistim/Puregon, a follicle-stimulating hormone for infertility; Esmeron/Zemuron, a muscle relaxant;

Akzo Nobel Unit for $14.4 Billion  -  Mar 12, 2007
Wall Street Journal (subscription),Organon's current drugs include the infertility treatment Follistim/Puregon, the muscle relaxant Esmeron/Zemuron and contraception treatments NuvaRing and

Schering-Plough Acquiring Organan BioSciences For $14.4 Billion  -  Mar 12, 2007
Manufacturing.net,Organon BioSciences' pharmaceutical business, Organon, had sales of $3.4 billion in 2006, including products such as Follistim/Puregon,

Akzo Nobel Annual Results 2006: Record Year  -  Feb 15, 2007
PharmaLive.com (press release),...while biotechnology fertility product Puregon® / Follistim®—Organon’s best-selling product—had another record year, with sales increasing by 8%.

Azko's Organon sales climb 8%, IPO in next few weeks  -  Feb 15, 2007
Pharma Times (subscription),The infertility treatment Puregon/Follistim (follitropin beta) - Organon's number one product - achieved a record result, rising 8% to 384 million euros,

Selling yourself short?  -  Feb 5, 2007
Spectator Eau Claire (subscription),The injections contain Fertinex, Follistim or Gonal-f, all of which are follicle-stimulating hormone (FSH) recombinant drugs. The FSH injections stimulate

Shots, eggs, embryos and a big dose of hope  Oct 29, 2006
At night, she gave herself two shots that stimulated egg production — Follistim (derived from the ovarian cells of Chinese hamsters) and Repronex (extracted ... -Los Angeles Times, Publicado: Sab Oct 14, 2006 5:01 pm Asunto: Unless directed to do ...  Oct 14, 2006
Even after ed follicle stimulating hormone cating the child to the dangers, keep medicines stored in as follistim fe place and out of the reach of children. ... -Shell Security,

Serono swings to profit, ups 2006 outlook  Apr 20, 2006
Particularly in the US, Gonal-F has come under pricing pressure from Akzo Nobel NV's (AKZOY) rival product Puregon, also known as Follistim, which the Dutch ... - MarketWatch

Persbericht Akzo Nobel - resultaten 1ekw 2006  Apr 19, 2006
Infertility products also made a strong contribution with Puregon(R)/Follistim(R) up 14% to nearly euro 100 million per quarter. ... - BNR Nieuwsradio

Akzo Nobel: Q1 Revenues and Operational Earnings Substantially ...  Apr 20, 2006
...rates. Infertility products also made a strong contribution with Puregon®/Follistim® up 14% to nearly EUR 100 million per quarter. ... - PharmaLive.com





Akzo Nobel Pharma Preparing For the Future  Mar 27, 2006
...not only work to sustain leadership status in its traditional areas of gynecology (eg NuvaRing® and Livial®); fertility (Puregon Pen®/Follistim Pen®); and ... - PharmaLive.com

Akzo Nobel planning IPO for pharma business  Feb 7, 2006
The increase was attributed to strong performances from fertility treatment Puregon/Follistim (follitropin beta) and contraceptive Nuvaring (etonogestrel ... - Pharma Times (subscription),

Annual Results: 2005 Net Income Improves  Feb 6, 2006
Sales of contraceptive vaginal ring NuvaRing® grew autonomously 58% in 2005, while fertility treatment Puregon® /Follistim® became Organon's biggest selling ... - Nieuwsbank (persbericht)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional